Behind the bribes taken by De Lorenzo for having imposed the mandatory hepatitis B vaccination, there was a huge gain from two pharmaceutical companies and often the numbers are not properly quoted.
Merck Sharp & Dohme, with the Recombivax vaccine, went from:
- 2.104 packs sold in 1988
- 45.952 packs sold in 1989
- 106.007 packs sold in 1990
- 466.000 packs sold in 1991
- 1.400.000 packs sold in 1992
Smithkline Beecham, with Engerix B vaccine, went from:
- 4.720 packs sold in 1987
- 138.836 packs sold in 1988
- 241.000 packs sold in 1983
- 288.000 packs sold in 1990
- 1.600.000 packs sold in 1991
- 4.484.000 packs sold in 1992
In terms of turnover, things are even more conspicuous.
Merck Sharp & Dohme, with the Recombivax vaccine, went from:
- 880 million Lire of turnover in 1989
- 2.2 billion Lire of turnover in 1990
- 6.8 billion Lire of turnover in 1991
- 20 billion Lire of turnover in 1992
Smithkline Beecham, with Engerix B vaccine, went from:
- 7.6 billion Lire of turnover in 1989
- 13 billion Lire of turnover in 1990
- 40 billion Lire of turnover in 1991
- 89 billion Lire of turnover in 1992
